Muthusamy Shanmugam Sells 47,012 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 47,012 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $90.27, for a total transaction of $4,243,773.24. Following the sale, the chief operating officer owned 484,908 shares of the company’s stock, valued at $43,772,645.16. This represents a 8.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Thursday, August 21st, Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $90.44, for a total value of $4,792,234.72.
• On Friday, August 15th, Muthusamy Shanmugam sold 52,990 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $87.15, for a total value of $4,618,078.50.
• On Thursday, August 14th, Muthusamy Shanmugam sold 47,010 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $89.48, for a total value of $4,206,454.80.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $91.01 on Friday. The firm has a market cap of $1.97 billion, a PE ratio of -118.19 and a beta of 0.61. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $92.53. The business’s fifty day simple moving average is $70.63 and its 200-day simple moving average is $65.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period last year, the company earned $1.02 EPS. The company’s quarterly revenue was up 53.2% on a year-over-year basis. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co increased its stake in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the period. Hohimer Wealth Management LLC grew its holdings in shares of ANI Pharmaceuticals by 5.2% during the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock worth $334,000 after buying an additional 247 shares during the last quarter. Legal & General Group Plc increased its position in ANI Pharmaceuticals by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company’s stock valued at $3,048,000 after acquiring an additional 351 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after acquiring an additional 364 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in ANI Pharmaceuticals by 10.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company’s stock valued at $285,000 after acquiring an additional 396 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANIP. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a report on Monday, August 11th. Piper Sandler reissued an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright restated a “buy” rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Finally, Guggenheim reiterated a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.